No credit card required
Free portfolio tracker:
One look. Clear picture of your portfolio.
Track multiple portfolios, currencies, and asset types in one simple dashboard. Understand risk, diversification, and performance without spreadsheets or brokerage linking.
Skip the trade-by-trade logging — just tell us what you hold today, and we reconstruct the history and performance for you. Prefer import? CSV works too.
No credit card required
Free AI token pool to start
Setup in 2 minutes
How portfolio tracking works
We organize and analyze everything for you
You get a clear, simple view of your portfolio
Fundamentals and sentiment, end to end
AI-powered instrument analysis built on fresh news & press releases
Every analysis is grounded in recent news, the latest company press releases, and current market data — then weighed against your own strategy, goals, and notes for that holding. Re-run it whenever something changes.
This is deep, single-instrument analysis — not a shallow summary. The scorecard, explicit risk flags, and four-part written report factor in the goals and notes you've set for that holding, so you can see exactly why the AI reaches its conclusion.
Sample analysis
Diagnostyka S.A. · DIAJul 09, 2026
Latest
12.0/15
Fundamental
4/5
The company posts an outstanding ROE (53.4%) and steady revenue growth (19.3% YoY). The key risks remain its high leverage (D/E of 197.5%) and weak current liquidity (current ratio of 0.73).
Sentiment
4/5
Excellent Q1 2026 results that beat the market consensus markedly improved sentiment around the company. The analysts’ average target price is 206.28 PLN, implying meaningful upside.
Strategy
4/5
The defensive, cycle-resilient healthcare sector is an excellent fit for long-term strategies. A regular dividend policy (4.40 PLN per share) and steady acquisitions support stable growth.
Target price: 206.28 zł
Risk flags
Valuation risk
Medium
Capital destruction
No
Guidance downgraded
No
Margin degradation
No
SBC dilution risk
No
Missing crucial data
No
Snapshot
Financial position & key ratios
Diagnostyka S.A. (DIA) is the undisputed leader of Poland’s medical laboratory market. The current share price of 171.90 PLN sits above the 50-day moving average (163.95 PLN) but below the 200-day average (180.80 PLN). On profitability the company impresses with an ROE of 53.41% and steady double-digit revenue growth (19.3% YoY). The weaker side of the balance sheet is liquidity – a current ratio of 0.73 – and high net debt relative to equity (197.49%), both stemming from the nature of its rapid expansion and the leasing of medical infrastructure. At a P/E of 22.21 the market valuation already prices in considerable growth expectations from investors.
Search
Market sentiment & recommendations
The consensus among analysts covering the company is highly optimistic and points unambiguously to a buy rating. The average target price set by experts is 206.28 PLN, which at the current price implies roughly 20% upside for the shares. Recent brokerage analyses and valuations place fair value in the 188 PLN to 217 PLN range. Positive investor sentiment was further reinforced after the May quarterly report, which dispelled concerns about a slowdown in the group’s organic growth.
Press
Latest events & dividend
The most important catalyst for the shares recently was the first-quarter 2026 results. The company reported net profit of 82.55 million PLN (up nearly 13% YoY), clearly beating market expectations of 72.5 million PLN. Sales revenue rose 13.4% YoY to 670.9 million PLN. In parallel, the Annual General Meeting of 25 May 2026 approved a 2025 dividend of 4.40 PLN per share, giving a dividend yield of about 2.54%. The record date fell on 2 June, with the payment date set for 16 June 2026. Strategically, management signalled scaling back capital-intensive acquisitions in imaging diagnostics in favour of developing high-margin B2C services that do not require NFZ (public payer) contracts. In the first quarter alone, however, the company completed as many as 8 smaller acquisitions of laboratory operators for a combined 31.9 million PLN.
Verdict
Summary & outlook
Diagnostyka S.A. proves it can effectively monetize its dominant market position, generating stable cash flows. The combination of the defensive nature of the medical sector, solid earnings growth and a regularly paid dividend (4.40 PLN/share) makes the company an attractive proposition for investors building a long-term income portfolio. The main risk factor remains its high leverage, which in an environment of elevated interest rates could raise the cost of financing further acquisitions. The key to sustaining the rally will be the successful integration of the acquired laboratories and success in winning private (B2C) customers, which will help keep margins high.
Explicit risk flags
Every analysis ends with a clear valuation-risk rating and a set of warning flags — no hidden reasoning, surfaced right next to the scorecard.
Valuation risk: high / medium / low
Capital destructionGuidance downgradeMargin degradationSBC dilution riskMissing crucial data
This is a sample analysis based on public market data.
On your account, you get full AI analyses for every instrument, complete history, and personalized re-evaluation triggers.
Raw verdicts, straight from the source
Portfolio Roast: brutally honest AI analysis from legendary investors
Get a sharp, no-fluff portfolio review in the voice of a legendary investor — pointed, opinionated, and focused on the mistakes that actually cost you money.
Privacy by design: the analysis only ever sees your allocation percentages. Monetary amounts never leave your account.
Sample roast
Cathie Wood's 4.5/10 Roast: Ditch the Emerging Market Index Trap
Cathie Wood is roasting your portfolio
Intro
A Linear Map for an Exponential World
When I look at this portfolio, I see an investor who realizes that the traditional Western growth engines are slowing down. You have heavily pivoted—nearly 95% of your geographic exposure is dedicated to Emerging Markets. I appreciate the desire to look for new horizons. But true growth in the 2020s isn't defined by geographic borders; it is defined by technological frontiers. You are looking for the future on a map, while we at ARK are looking for it in the convergence of innovation platforms.
You are sitting on a 5.5% cash reserve. That is an acceptable tactical buffer to have on hand for buying dips when the broader market panics. But make no mistake: in an age of exponential disruption, idle cash is dead capital. Every day you sit in cash or legacy assets, you are actively betting against Wright's Law and the deflationary cost curves that are reshaping the global economy. You have glimpses of true visionary brilliance here, but they are buried under a mountain of backward-looking, linear assets that belong to the last economic cycle. Let's look at why your portfolio is straddling the fence between disruption and decay.
Intro
A short opening that frames the portfolio in the roaster's own voice and sets the tone of the review.
Analysis
A breakdown of asset allocation, sector concentration, geographic diversification, and overall portfolio risk.
Red flags
The weak spots and blind spots the roaster wants you to confront — concentration, overlap, hidden risk, and bad habits.
Verdict
A single score out of 10 plus 3–5 concrete, actionable recommendations tailored to your portfolio.
Legendary investor personas, each with its own philosophy
Warren Buffett
Value Investing
Stanley Druckenmiller
Global Macro
Cathie Wood
Disruptive Innovation
Nancy Pelosi
Legislative Alpha
Ray Dalio
Macro / Risk Parity
Michael Burry
Contrarian Deep Value
Jim Simons
Quantitative
Michael Saylor
Bitcoin Maximalism
Kevin O'Leary
Cashflow & Dividends
Bill Ackman
Activist / Concentrated
Peter Lynch
Growth at a Reasonable Price
Howard Marks
Risk & Market Cycles
TD
The Dividend Grandpa
Income & Dividends
TM
The Momentum Chaser
Momentum & Growth
TS
The Spreadsheet Monk
Fundamental Value
TI
The Index Robot
Passive Indexing
TD
The Degenerate
High-Risk Speculation
TD
The Doomsday Prepper
Defensive & Hard Assets
Your investments won't organize themselves.
Start now — you're risking nothing.
No credit card. No catches. Just sign in with Google.
Everything you need to see your whole portfolio clearly
One calm dashboard for every portfolio, currency, and asset type you hold.
Free forever, no card
Unlimited portfolios, 30+ currencies, full analytics, breakdowns, and benchmark comparison — all free, no credit card. The only paid extra is AI analysis, once your included token pool runs out.
Every account in one place
Brokerages, retirement accounts, crypto wallets, cash, and property — combined into one real net worth instead of a number scattered across five apps.
Import in seconds — even from a screenshot
Bring holdings in from a CSV, a broker statement, or a screenshot of your positions. From a full statement we replay your trades into a dated timeline, so your charts show real past performance — not a flat line from today.
Many currencies, one honest number
Hold USD, EUR, PLN, GBP, JPY and more at once. Every value is converted at the real historical rate, so your performance reflects currency moves instead of hiding them.
Tracks how you actually invest
Stocks, ETFs, bonds, deposits, crypto, REITs, cash, real estate, and private assets live side by side — not just the tickers your broker happens to support.
A structural health check, not a vibe
See how far your diversification, cash, and regional mix drift from the allocation targets you set. It's a deterministic read of your portfolio's structure — no black box, no score to obsess over.
AI research on any holding, on demand
Run a deep analysis of a single instrument built on the latest news and earnings — a transparent scorecard, explicit risk flags, and a written verdict that weighs the holding against your own goals and notes.
Private by design
No brokerage linking, no bank sync, no shared logins. You enter or import your own data and it stays on your side — files and screenshots are read to load your holdings, never stored.